Risk factors for mortality in patients admitted to intensive care units with pneumonia

Guowei Li, Deborah J Cook, Lehana Thabane, Jan O Friedrich, Tim M Crozier, John Muscedere, John Granton, Sangeeta Mehta, Steven C Reynolds, Renato D Lopes, Francois Lauzier, Andreas P Freitag, Mitchell A H Levine, PROTECT Investigators for the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Guowei Li, Deborah J Cook, Lehana Thabane, Jan O Friedrich, Tim M Crozier, John Muscedere, John Granton, Sangeeta Mehta, Steven C Reynolds, Renato D Lopes, Francois Lauzier, Andreas P Freitag, Mitchell A H Levine, PROTECT Investigators for the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group

Abstract

Background: Despite the high mortality in patients with pneumonia admitted to an ICU, data on risk factors for death remain limited.

Methods: In this secondary analysis of PROTECT (Prophylaxis for Thromboembolism in Critical Care Trial), we focused on the patients admitted to ICU with a primary diagnosis of pneumonia. The primary outcome for this study was 90-day hospital mortality and the secondary outcome was 90-day ICU mortality. Cox regression model was conducted to examine the relationship between baseline and time-dependent variables and hospital and ICU mortality.

Results: Six hundred sixty seven patients admitted with pneumonia (43.8 % females) were included in our analysis, with a mean age of 60.7 years and mean APACHE II score of 21.3. During follow-up, 111 patients (16.6 %) died in ICU and in total, 149 (22.3 %) died in hospital. Multivariable analysis demonstrated significant independent risk factors for hospital mortality including male sex (hazard ratio (HR) = 1.5, 95 % confidence interval (CI): 1.1 - 2.2, p-value = 0.021), higher APACHE II score (HR = 1.2, 95 % CI: 1.1 - 1.4, p-value < 0.001 for per-5 point increase), chronic heart failure (HR = 2.9, 95 % CI: 1.6 - 5.4, p-value = 0.001), and dialysis (time-dependent effect: HR = 2.7, 95 % CI: 1.3 - 5.7, p-value = 0.008). Higher APACHE II score (HR = 1.2, 95 % CI: 1.1 - 1.4, p-value = 0.002 for per-5 point increase) and chronic heart failure (HR = 2.6, 95 % CI: 1.3 - 5.0, p-value = 0.004) were significantly related to risk of death in the ICU.

Conclusion: In this study using data from a multicenter thromboprophylaxis trial, we found that male sex, higher APACHE II score on admission, chronic heart failure, and dialysis were independently associated with risk of hospital mortality in patients admitted to ICU with pneumonia. While high illness severity score, presence of a serious comorbidity (heart failure) and need for an advanced life support (dialysis) are not unexpected risk factors of mortality, male sex might necessitate further exploration. More studies are warranted to clarify the effect of these risk factors on survival in critically ill patients admitted to ICU with pneumonia.

Trial registration: ClinicalTrials.gov Identifier: NCT00182143 .

Keywords: Intensive care; Mortality; Pneumonia; Risk factor.

Figures

Fig. 1
Fig. 1
KM curve for 90-day Hospital mortality
Fig. 2
Fig. 2
KM curve for 90-day ICU mortality

References

    1. Mattila JT, Fine MJ, Limper AH, Murray PR, Chen BB, Lin PL. Pneumonia. Treatment and diagnosis. Ann Am Thor Soc. 2014;11(Suppl 4):S189–92. doi: 10.1513/AnnalsATS.201401-027PL.
    1. Society AT. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416. doi: 10.1164/rccm.200405-644ST.
    1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Supplement 2):S27–S72. doi: 10.1086/511159.
    1. Lim WS, Baudouin S, George R, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1–iii55. doi: 10.1136/thx.2009.121434.
    1. Vallés J, Martin-Loeches I, Torres A, et al. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med. 2014;40(4):572–81. doi: 10.1007/s00134-014-3239-2.
    1. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996;275(2):134–41. doi: 10.1001/jama.1996.03530260048030.
    1. Rodriguez A, Lisboa T, Blot S, et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med. 2009;35(3):430–8. doi: 10.1007/s00134-008-1363-6.
    1. Walden AP, Clarke GM, McKechnie S, et al. Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit Care. 2014;18(2):R58. doi: 10.1186/cc13812.
    1. Venditti M, Falcone M, Corrao S, Licata G, Serra P. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150(1):19–26. doi: 10.7326/0003-4819-150-1-200901060-00005.
    1. Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis. 2011;53(2):107–13. doi: 10.1093/cid/cir274.
    1. Roquilly A, Marret E, Abraham E, Asehnoune K. Clin Infect Dis. 2014;60(1):64–75. doi: 10.1093/cid/ciu740.
    1. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J. 2006;27(6):1210–6. doi: 10.1183/09031936.06.00139305.
    1. Tejerina E, Frutos-Vivar F, Restrepo MI, et al. Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. J Crit Care. 2005;20(3):230–8. doi: 10.1016/j.jcrc.2005.05.010.
    1. Blot S, Koulenti D, Dimopoulos G, et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, Old, and very Old critically Ill patients*. Crit Care Med. 2014;42(3):601–9. doi: 10.1097/01.ccm.0000435665.07446.50.
    1. Lynch JP., 3rd Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest. 2001;119(2 Suppl):373S–84S. doi: 10.1378/chest.119.2_suppl.373S.
    1. Combes A, Luyt C-E, Trouillet J-L, Nieszkowska A, Chastre J. Gender impact on the outcomes of critically ill patients with nosocomial infections*. Crit Care Med. 2009;37(9):2506–11. doi: 10.1097/CCM.0b013e3181a569df.
    1. Gastmeier P, Sohr D, Geffers C, Behnke M, Ruden H. Risk factors for death due to nosocomial infection in intensive care unit patients: findings from the Krankenhaus Infektions Surveillance System. Infect Control Hosp Epidemiol. 2007;28(4):466–72. doi: 10.1086/510810.
    1. Oz F, Gul S, Kaya MG, et al. Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial. Coron Artery Dis. 2013;24(3):231–7. doi: 10.1097/MCA.0b013e32835d7610.
    1. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 2008;121(11):1002–7. doi: 10.1016/j.amjmed.2008.06.030.
    1. Winning J, Neumann J, Kohl M, et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med. 2010;38(1):32–7. doi: 10.1097/CCM.0b013e3181b4275c.
    1. Losche W, Boettel J, Kabisch B, Winning J, Claus RA, Bauer M. Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients? Thromb. 2012;2012:720254. doi: 10.1155/2012/720254.
    1. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999;20(1):145–57. doi: 10.1146/annurev.publhealth.20.1.145.
    1. Cook D, Meade M, Guyatt G, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14):1305–14. doi: 10.1056/NEJMoa1014475.
    1. Cook D, Meade M, Guyatt G, et al. PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan. J Crit Care. 2011;26(2):223. doi: 10.1016/j.jcrc.2011.02.010.
    1. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–26. doi: 10.1093/biomet/81.3.515.
    1. Bodi M, Rodriguez A, Sole-Violan J, et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005;41(12):1709–16. doi: 10.1086/498119.
    1. Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J. 2004;24(5):779–85. doi: 10.1183/09031936.04.00119503.
    1. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36(4):612–20. doi: 10.1007/s00134-009-1730-y.
    1. Adrie C, Azoulay E, Francais A, et al. Influence of gender on the outcome of severe sepsis: a reappraisal. Chest. 2007;132(6):1786–93. doi: 10.1378/chest.07-0420.
    1. Agarwal R, Aggarwal AN, Gupta D, Behera D, Jindal SK. Etiology and outcomes of pulmonary and extrapulmonary acute lung injury/ARDS in a respiratory ICU in North India. Chest. 2006;130(3):724–9. doi: 10.1378/chest.130.3.724.
    1. Arnold FW, Wiemken TL, Peyrani P, Mirsaeidi M, Ramirez JA. Outcomes in females hospitalised with community-acquired pneumonia are worse than in males. Eur Respir J. 2013;41(5):1135–40. doi: 10.1183/09031936.00046212.
    1. May AK, Dossett LA, Norris PR, et al. Estradiol is associated with mortality in critically ill trauma and surgical patients. Crit Care Med. 2008;36(1):62–8. doi: 10.1097/01.CCM.0000292015.16171.6D.
    1. Diodato MD, Knoferl MW, Schwacha MG, Bland KI, Chaudry IH. Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. Cytokine. 2001;14(3):162–9. doi: 10.1006/cyto.2001.0861.
    1. Alp E, Guven M, Yildiz O, Aygen B, Voss A, Doganay M. Incidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective study. Ann Clin Microbiol Antimicrob. 2004;3:17. doi: 10.1186/1476-0711-3-17.
    1. Thomsen RW, Kasatpibal N, Riis A, Norgaard M, Sorensen HT. The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study. J Gen Intern Med. 2008;23(9):1407–13. doi: 10.1007/s11606-008-0672-3.
    1. Sirvent JM, de la Torre CM, Lorencio C, et al. Predictive factors of mortality in severe community-acquired pneumonia: a model with data on the first 24h of ICU admission. Medicina intensiva/Sociedad Espanola de Medicina Intensiva y Unidades Coronarias. 2013;37(5):308–15. doi: 10.1016/j.medin.2013.03.003.
    1. Almirall J, Mesalles E, Klamburg J, Parra O, Agudo A. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest. 1995;107(2):511–6. doi: 10.1378/chest.107.2.511.
    1. Lim W, Meade M, Lauzier F, et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. Crit Care Med. 2015;43(2):401–10. doi: 10.1097/CCM.0000000000000713.
    1. Otto GP, Sossdorf M, Boettel J, et al. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets. 2013;24(6):480–5. doi: 10.3109/09537104.2012.724482.
    1. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care. 2010;25(4):656. doi: 10.1016/j.jcrc.2010.02.013.
    1. Papazian L, Roch A, Charles PE, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA. 2013;310(16):1692–700. doi: 10.1001/jama.2013.280031.
    1. Kruger P, Bailey M, Bellomo R, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med. 2013;187(7):743–50. doi: 10.1164/rccm.201209-1718OC.
    1. Prasad V. The overdiagnosis of pneumonia. Cleve Clin J Med. 2013;80(10):616–8. doi: 10.3949/ccjm.80a.12180.
    1. Nussenblatt V, Avdic E, Berenholtz S, et al. Ventilator-associated pneumonia: overdiagnosis and treatment are common in medical and surgical intensive care units. Infect Control Hosp Epidemiol. 2014;35(3):278–84. doi: 10.1086/675279.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi